Latest news with #NaturePortfolio
Zawya
19-05-2025
- Health
- Zawya
LiveSpo® NAVAX Nasal-Spray Probiotics: A New Approach in Supporting the Treatment of Rhinosinusitis and Otitis Media
HANOI, VIETNAM - Media OutReach Newswire - 19 May 2025 - LiveSpo® NAVAX – a nasal-spray probiotic product developed by Vietnamese scientists – has recently been published in the high-ranking international scientific journal Scientific Reports-Nature, recognizing its effectiveness in supporting the treatment of rhinosinusitis and otitis media in children. This marks the third consecutive study on the product published in a prestigious international scientific platform, reinforcing a promising new direction in non-antibiotic respiratory care. The findings from the clinical study, conducted Thai Binh University of Medicine and Pharmacy in collaboration with other institutions, was published on January 27, 2025, in Scientific Reports-Nature, a renowned journal under the Nature Portfolio (UK). The results demonstrated significant effectiveness in children within just 3–7 days of use. Additionally, data also showed positive improvements in adults, highlighting the product's potential for broader application in the future. The study was carried out from November 2023 to December 2024 with the participation of 126 patients, including both children and adults. Among children with acute rhinosinusitis and perforated acute otitis media, the treatment results were particularly notable: after 3 days of using LiveSpo® NAVAX, nasal congestion decreased by 68%, twice as much as the saline group. After 7 days, 97% of the children had no more nasal discharge, and 100% had no more ear discharge. The concentration of pathogenic bacteria Streptococcus pneumoniae in nasal and ear secretions dropped more than 1,200 times. Importantly, no side effects were recorded during the entire trial – even in children with weakened immune systems. In the adult group with acute sinusitis, symptoms such as nasal congestion, facial pain, and purulent discharge improved significantly after 3 days of use – with reductions of 53%, 78%, and 61%, respectively. After 7 days, 91% of patients no longer experienced nasal discharge. Laboratory results showed a substantial reduction in pathogenic bacteria: Streptococcus pneumoniae decreased over 380-fold and Haemophilus influenzae decreased over 49,000-fold compared to the Control group receiving physiological saline According to the research team, the effectiveness of LiveSpo® NAVAX origins from its ability to modulate local inflammatory responses and enhance mucosal immunity through the competitive biological mechanism of spore-forming Bacillus probiotics. Inflammatory markers such as IL-6, IL-8, and TNF-α significantly decreased, while levels of IgA – a key protective antibody at the mucosal surface – increased, contributing to the restoration of the nose and ear's natural defense barrier. This study not only adds to the growing body of scientific evidence supporting LiveSpo® NAVAX's efficacy in respiratory care but also affirms Vietnam's biomedical research capabilities on the international scientific map. It paves the way for a safe, sustainable respiratory treatment alternative that reduces reliance on antibiotics – especially for vulnerable groups like children. Dr. Nguyen Hoa Anh, Chairman and Founder of LiveSpo Pharma, shared: "At LiveSpo, we prioritize the research and development of internationally standardized products, combining modern medicine with advanced probiotic technology to deliver safe and effective health solutions for the community – all with a vision of A Future Without Antibiotics." References: Khieu TH, Le DP, Nguyen BT, Ngo BT, Chu HT, Truong DM, Nguyen HM, Nguyen AH, Pham TD, Van Nguyen AT. Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial. Sci Rep. 2025 Jan 27;15(1):3410. doi: 10.1038/s41598-025-87372-2. PMID: 39870748; PMCID: PMC11772584. Hashtag: #LiveSpo The issuer is solely responsible for the content of this announcement. About LiveSpo Pharma LiveSpo is an R&D, manufacturing, and distribution brand of Clinically Proven Medical Probiotics, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for "A Future Without Antibiotics". Our vision: In 2027, LiveSpo will have 1.5 million consumers who use Spore probiotics for digestive and respiratory health instead of antibiotics, with outstanding benefits and customer experiences. Established since 2010 by Dr. Nguyen Hoa Anh (Dr. ANH) and his colleagues, LiveSpo has remained steadfast in its belief that Live Probiotic Spores - Spobiotic - will pave the way to a future without antibiotics for everyone. Hotline: 1800.088808 Website: LiveSpo
Yahoo
19-05-2025
- Health
- Yahoo
LiveSpo(R) NAVAX Nasal-Spray Probiotics: A New Approach in Supporting the Treatment of Rhinosinusitis and Otitis Media
HANOI, VN / / May 19, 2025 / LiveSpo® NAVAX - a nasal-spray probiotic product developed by Vietnamese scientists - has recently been published in the high-ranking international scientific journal Scientific Reports-Nature, recognizing its effectiveness in supporting the treatment of rhinosinusitis and otitis media in children. This marks the third consecutive study on the product published in a prestigious international scientific platform, reinforcing a promising new direction in non-antibiotic respiratory care. The findings from the clinical study, conducted Thai Binh University of Medicine and Pharmacy in collaboration with other institutions, was published on January 27, 2025, in Scientific Reports-Nature, a renowned journal under the Nature Portfolio (UK). The results demonstrated significant effectiveness in children within just 3-7 days of use. Additionally, data also showed positive improvements in adults, highlighting the product's potential for broader application in the future. The study was carried out from November 2023 to December 2024 with the participation of 126 patients, including both children and adults. Among children with acute rhinosinusitis and perforated acute otitis media, the treatment results were particularly notable: after 3 days of using LiveSpo® NAVAX, nasal congestion decreased by 68%, twice as much as the saline group. After 7 days, 97% of the children had no more nasal discharge, and 100% had no more ear discharge. The concentration of pathogenic bacteria Streptococcus pneumoniae in nasal and ear secretions dropped more than 1,200 times. Importantly, no side effects were recorded during the entire trial - even in children with weakened immune systems. In the adult group with acute sinusitis, symptoms such as nasal congestion, facial pain, and purulent discharge improved significantly after 3 days of use - with reductions of 53%, 78%, and 61%, respectively. After 7 days, 91% of patients no longer experienced nasal discharge. Laboratory results showed a substantial reduction in pathogenic bacteria: Streptococcus pneumoniae decreased over 380-fold and Haemophilus influenzae decreased over 49,000-fold compared to the Control group receiving physiological saline According to the research team, the effectiveness of LiveSpo® NAVAX origins from its ability to modulate local inflammatory responses and enhance mucosal immunity through the competitive biological mechanism of spore-forming Bacillus probiotics. Inflammatory markers such as IL-6, IL-8, and TNF-α significantly decreased, while levels of IgA - a key protective antibody at the mucosal surface - increased, contributing to the restoration of the nose and ear's natural defense barrier. This study not only adds to the growing body of scientific evidence supporting LiveSpo® NAVAX's efficacy in respiratory care but also affirms Vietnam's biomedical research capabilities on the international scientific map. It paves the way for a safe, sustainable respiratory treatment alternative that reduces reliance on antibiotics - especially for vulnerable groups like children. Dr. Nguyen Hoa Anh, Chairman and Founder of LiveSpo Pharma, shared:"At LiveSpo, we prioritize the research and development of internationally standardized products, combining modern medicine with advanced probiotic technology to deliver safe and effective health solutions for the community - all with a vision of A Future Without Antibiotics." References:Khieu TH, Le DP, Nguyen BT, Ngo BT, Chu HT, Truong DM, Nguyen HM, Nguyen AH, Pham TD, Van Nguyen AT. Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial. Sci Rep. 2025 Jan 27;15(1):3410. doi: 10.1038/s41598-025-87372-2. PMID: 39870748; PMCID: PMC11772584. About LiveSpo Pharma LiveSpo is an R&D, manufacturing, and distribution brand of Clinically Proven Medical Probiotics, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for "A Future Without Antibiotics". Our vision: In 2027, LiveSpo will have 1.5 million consumers who use Spore probiotics for digestive and respiratory health instead of antibiotics, with outstanding benefits and customer experiences. Established since 2010 by Dr. Nguyen Hoa Anh (Dr. ANH) and his colleagues, LiveSpo has remained steadfast in its belief that Live Probiotic Spores - Spobiotic - will pave the way to a future without antibiotics for everyone. Hotline: 1800.088808 Website: Media Contact SOURCE: LiveSpo View the original press release on ACCESS Newswire
Arabian Post
19-05-2025
- Health
- Arabian Post
LiveSpo® NAVAX Nasal-Spray Probiotics: A New Approach in Supporting the Treatment of Rhinosinusitis and Otitis Media
The findings from the clinical study, conducted Thai Binh University of Medicine and Pharmacy in collaboration with other institutions, was published on January 27, 2025, in Scientific Reports-Nature, a renowned journal under the Nature Portfolio (UK). The results demonstrated significant effectiveness in children within just 3–7 days of use. Additionally, data also showed positive improvements in adults, highlighting the product's potential for broader application in the future. The study was carried out from November 2023 to December 2024 with the participation of 126 patients, including both children and adults. Among children with acute rhinosinusitis and perforated acute otitis media, the treatment results were particularly notable: after 3 days of using LiveSpo® NAVAX, nasal congestion decreased by 68%, twice as much as the saline group. After 7 days, 97% of the children had no more nasal discharge, and 100% had no more ear discharge. The concentration of pathogenic bacteria Streptococcus pneumoniae in nasal and ear secretions dropped more than 1,200 times. Importantly, no side effects were recorded during the entire trial – even in children with weakened immune systems. In the adult group with acute sinusitis, symptoms such as nasal congestion, facial pain, and purulent discharge improved significantly after 3 days of use – with reductions of 53%, 78%, and 61%, respectively. After 7 days, 91% of patients no longer experienced nasal discharge. Laboratory results showed a substantial reduction in pathogenic bacteria: Streptococcus pneumoniae decreased over 380-fold and Haemophilus influenzae decreased over 49,000-fold compared to the Control group receiving physiological saline According to the research team, the effectiveness of LiveSpo® NAVAX origins from its ability to modulate local inflammatory responses and enhance mucosal immunity through the competitive biological mechanism of spore-forming Bacillus probiotics. Inflammatory markers such as IL-6, IL-8, and TNF-α significantly decreased, while levels of IgA – a key protective antibody at the mucosal surface – increased, contributing to the restoration of the nose and ear's natural defense barrier. This study not only adds to the growing body of scientific evidence supporting LiveSpo® NAVAX's efficacy in respiratory care but also affirms Vietnam's biomedical research capabilities on the international scientific map. It paves the way for a safe, sustainable respiratory treatment alternative that reduces reliance on antibiotics – especially for vulnerable groups like children. Dr. Nguyen Hoa Anh, Chairman and Founder of LiveSpo Pharma, shared: 'At LiveSpo, we prioritize the research and development of internationally standardized products, combining modern medicine with advanced probiotic technology to deliver safe and effective health solutions for the community – all with a vision of A Future Without Antibiotics.' References: Khieu TH, Le DP, Nguyen BT, Ngo BT, Chu HT, Truong DM, Nguyen HM, Nguyen AH, Pham TD, Van Nguyen AT. Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial. Sci Rep. 2025 Jan 27;15(1):3410. doi: 10.1038/s41598-025-87372-2. PMID: 39870748; PMCID: PMC11772584. Hashtag: #LiveSpo The issuer is solely responsible for the content of this announcement. About LiveSpo Pharma LiveSpo is an R&D, manufacturing, and distribution brand of Clinically Proven Medical Probiotics, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for 'A Future Without Antibiotics'. Our vision: In 2027, LiveSpo will have 1.5 million consumers who use Spore probiotics for digestive and respiratory health instead of antibiotics, with outstanding benefits and customer experiences. Established since 2010 by Dr. Nguyen Hoa Anh (Dr. ANH) and his colleagues, LiveSpo has remained steadfast in its belief that Live Probiotic Spores – Spobiotic – will pave the way to a future without antibiotics for everyone. Hotline: 1800.088808 Website:
Time of India
14-05-2025
- Health
- Time of India
New health emergency in Canada? Inflammatory Bowel Disease cases skyrocket, according to a global study
Canada is facing a health crisis in the making, as the number of people living with inflammatory bowel disease ( IBD ) is expected to surge dramatically by 2045, according to a new global study published in Nature Portfolio which is co-led by Dr. Gilaad Kaplan from the University of Calgary and Professor Siew Ng from the Chinese University of Hong Kong. The research spanned more than a century and analyzed data from over 500 population-based studies across 82 countries, and identified four distinct stages in the global evolution of IBD: Emergence, Acceleration, Compounding Prevalence, and Prevalence Equilibrium. Surge in inflammatory bowel disease in Canada Canada is currently in the third stage, i.e, Compounding Prevalence, characterized by a growing number of individuals living with IBD, particularly among seniors. (Join our ETNRI WhatsApp channel for all the latest updates) In 2025, approximately 0.8% of Canadians are projected to be living with IBD, a figure expected to climb to 1% by the 2030s and 2040s. Live Events By the 2030s, over 400,000 Canadians are anticipated to be living with IBD, up from an estimated 322,600 in 2023. This surge poses significant challenges for Canada's healthcare system, which must adapt to manage both new diagnoses and the aging population of IBD patients. Dr. Kaplan emphasizes the dual challenge facing healthcare providers: managing new diagnoses in younger individuals while also addressing the needs of an aging IBD population. 'We're managing new diagnoses in young individuals, but we're also seeing an aging IBD population,' Kaplan explained. 'People diagnosed with Crohn's in their 30s in the 1990s will be in their 70s by the 2030s. That means we'll have to manage IBD alongside age-related comorbidities like cardiovascular disease, cancer , and dementia.' IBD typically starts between 20 and 40 years of age and can cause lifelong symptoms . The study says IBD was first recognized in the 19th century, and in the early 20th century, was considered 'a rare disease among the descendants of Europeans who colonized North America and Oceania.' Once considered a disease of the Western world, Kaplan said it's now a truly global condition. This shift is attributed to changes in diet, lifestyle, and environment associated with industrialization and urbanization, which affect the gut microbiome, a key factor in IBD development. In response to these trends, Dr. Kaplan and Professor Ng advocate for a dual approach, prioritizing prevention by investigating environmental causes of IBD, such as diet, and innovating healthcare systems to provide accessible, equitable, and affordable care for all patients. Kaplan adds that Canada's leadership in IBD care and research is also an opportunity. 'We're seen as a guiding light globally,' Kaplan said. 'Countries like those in Asia and Latin America are just now seeing a rise in IBD. We can learn from it, and it can give us clues to what is environmentally driving the disease, and change those things in practice in Canada. While Canada is not yet at Stage 4, the study expects it to reach this point in the coming decades, if current trends hold. FAQs What is Inflammatory Bowel Disease (IBD)? Inflammatory bowel disease (IBD) refers to a group of chronic conditions that cause inflammation in the digestive tract. The two most common types of IBD are Crohn's disease and ulcerative colitis. These conditions can lead to symptoms that significantly affect a person's daily life and well-being. What are the symptoms of IBD? IBD symptoms include abdominal pain, diarrhea (sometimes with blood), rectal bleeding, weight loss, fatigue, loss of appetite, and sometimes fever. People with IBD may also experience an urgency to have bowel movements and anemia. How is IBD treated? There is no cure for IBD, but treatment focuses on managing symptoms and reducing inflammation. Medications like anti-inflammatory drugs, immunosuppressants, and biologics are commonly used. Dietary changes and surgery may be necessary in severe cases, and supportive care such as hydration and nutrition is often part of the treatment plan. Can IBD lead to death? While IBD itself is not typically fatal, it can cause severe complications like bowel perforations, abscesses, or infections. Long-term conditions like ulcerative colitis may also increase the risk of colon cancer. Proper treatment and management are essential to reducing risks and improving quality of life.
